Department of Radiation Oncology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
Division of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):958-967. doi: 10.1016/j.ijrobp.2019.12.037. Epub 2020 Jan 25.
In this multicenter phase 2 feasibility study, we investigated the impact of preoperative accelerated partial breast irradiation (PAPBI) on local control, breast fibrosis, and cosmetic outcome.
Women aged >60 years with an invasive, unifocal (mammography and magnetic resonance imaging), nonlobular adenocarcinoma of the breast were treated with PAPBI. Six weeks after radiation therapy, a wide local excision was performed. Radiation therapy consisted of 10 × 4 Gy (2010-2013) or 5 × 6 Gy (after 2013) to the tumor (gross target volume) with a 25 mm margin (20 mm from gross target volume to clinical target volume, 5 mm planning target volume).
One hundred thirty-three patients treated between 2010 and 2016 were analyzed with a median follow-up of 5.0 years (0.9-8.8 years). Seventy-eight (59%) patients were treated with 10 × 4 Gy in 2 weeks and 55 (41%) patients with 5 × 6 Gy in 1 week. Eighteen postoperative complications (14%) occurred in 15 patients (11%). The proportion of patients with no to mild fibrosis in the treated part of the breast at 2 years and later time points was around 90%. Cosmesis improved over time in several patients: excellent to good cosmetic score as rated by the physician was 68% at 6 months and 92% at 5 years. Seventy-seven percent (6 months) to 82% (5 years) of patients were "satisfied" or "very satisfied" with their cosmetic outcome. Three recurrences were detected in the biopsy track and 1 recurrence in the ipsilateral breast.
PAPBI is a feasible method with a low postoperative complication rate, limited fibrosis, and good to excellent cosmetic outcome. The local recurrence rate was 3% at 5 years; however, no local recurrences were observed since removal of the needle biopsy track.
在这项多中心 2 期可行性研究中,我们研究了术前加速部分乳房照射(PAPBI)对局部控制、乳房纤维化和美容效果的影响。
对年龄 > 60 岁的女性进行了研究,这些女性患有浸润性、单灶(乳房 X 线照相术和磁共振成像)、非小叶腺癌乳腺癌,接受了 PAPBI 治疗。放射治疗 6 周后进行广泛局部切除。放射治疗包括对肿瘤(大体肿瘤靶区)进行 10 × 4 Gy(2010-2013 年)或 5 × 6 Gy(2013 年后)照射,有 25 mm 边界(从大体肿瘤靶区到临床靶区 20 mm,计划靶区 5 mm)。
对 2010 年至 2016 年间接受治疗的 133 例患者进行了分析,中位随访时间为 5.0 年(0.9-8.8 年)。78 例(59%)患者接受 10 × 4 Gy 治疗 2 周,55 例(41%)患者接受 5 × 6 Gy 治疗 1 周。15 例患者发生 18 例术后并发症(14%)。在治疗后的乳房中,2 年及以后无至轻度纤维化的患者比例约为 90%。在一些患者中,美容效果随时间的推移而改善:医生评定的优秀至良好美容评分在 6 个月时为 68%,在 5 年时为 92%。77%(6 个月)至 82%(5 年)的患者对他们的美容效果表示“满意”或“非常满意”。在活检部位检测到 3 次复发,同侧乳房 1 次复发。
PAPBI 是一种可行的方法,其术后并发症发生率低,纤维化程度有限,美容效果好至优秀。5 年局部复发率为 3%;然而,自去除针活检部位以来,未观察到局部复发。